Skip to main content

Advertisement

SpringerLink
Log in

Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer

  • REVIEW ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Lung cancer is the leading cause of cancer death worldwide, and most patients die of metastatic disease. Angiogenesis, namely, neovascularization from preexisting vasculature, is necessary for tumor growth in both primary and distant organs to supply oxygen and nutrition. Angiogenesis consists of sprouting and nonsprouting (the enlargement, splitting, and fusion of preexisting vessels) processes, and both can occur concurrently. The growth of non-small cell lung cancer (NSCLC), which accounts for more than 80% of all lung cancers, is usually dependent on angiogenesis, which is regulated by complex mechanisms in the presence of various angiogenesis-related molecules. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is one of the most potent angiogenic molecules, while also regulating both angiogenesis and vascular permeability and hence promoting tumor progression and the development of malignant pleural effusions in NSCLC. Recent clinical trials showed that the anti-VEGF antibody bevacizumab, combined with standard first-line chemotherapy, provided a statistically and clinically significant survival advantage with tolerable toxicity. In addition, the combined use of the anti-VEGF antibody with an inhibitor of epidermal growth factor receptor (EGFR) has also shown favorable antitumor efficiency. These successes proved the validity of an antivasculature strategy for NSCLC. Furthermore, a large number of antivasculature agents have been shown to be effective against multiple targets. The efficiency of these compounds is currently being investigated in clinical trials for NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Editorial Board of the Cancer Statistics in Japan (2001) Foundation for Promotion of Cancer Research, Tokyo

  2. LAG Ries MP Eisner CL Kosary (2001) SEER cancer statistics review, 1973–1998 National Cancer Institute Bethesda, MD

    Google Scholar 

  3. M Fukuoka S Yano G Giaccone et al. (2003) ArticleTitleMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2237–2246 Occurrence Handle10.1200/JCO.2003.10.038 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGqu7w%3D Occurrence Handle12748244

    Article  CAS  PubMed  Google Scholar 

  4. N Thatcher A Chang P Parikh et al. (2005) ArticleTitleGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527–1537 Occurrence Handle10.1016/S0140-6736(05)67625-8 Occurrence Handle1:CAS:528:DC%2BD2MXhtFKhsbfP Occurrence Handle16257339

    Article  CAS  PubMed  Google Scholar 

  5. J Folkman (1971) ArticleTitleTumor angiogenesis: therapeutic implication N Engl J Med 285 182–186

    Google Scholar 

  6. RS Herbst A Onn A Sandler (2005) ArticleTitleAngiogenesis and lung cancer: prognostic and therapeutic implications J Clin Oncol 23 3243–3256 Occurrence Handle1:CAS:528:DC%2BD2MXltVWis7k%3D Occurrence Handle15886312

    CAS  PubMed  Google Scholar 

  7. S Yano Y Nishioka H Goto S Sone (2003) ArticleTitleMolecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules Cancer Sci 94 479–485 Occurrence Handle1:CAS:528:DC%2BD3sXmsFWltrw%3D Occurrence Handle12824870

    CAS  PubMed  Google Scholar 

  8. S Yano H Shinohara RS Herbst et al. (2000) ArticleTitleExpression of vascular endothelial growth factor is essential but not sufficient for production and growth of brain metastasis Cancer Res 60 4959–4967 Occurrence Handle1:CAS:528:DC%2BD3cXmsFWhsbk%3D Occurrence Handle10987313

    CAS  PubMed  Google Scholar 

  9. IJ Fidler S Yano R Zhang et al. (2002) ArticleTitleThe seed and soil hypothesis: vascularization and brain metastases Lancet Oncol 3 53–57 Occurrence Handle10.1016/S1470-2045(01)00622-2 Occurrence Handle1:CAS:528:DC%2BD38Xhtleitb0%3D Occurrence Handle11905606

    Article  CAS  PubMed  Google Scholar 

  10. F Pezzella U Pastorino E Tagliabue et al. (1997) ArticleTitleNon-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis Am J Pathol 151 1417–1423 Occurrence Handle1:STN:280:DyaK1c%2FitlKlsg%3D%3D Occurrence Handle9358768

    CAS  PubMed  Google Scholar 

  11. G Fontanini M Lucchi S Vignati et al. (1997) ArticleTitleAngiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study J Natl Cancer Inst 89 881–886 Occurrence Handle10.1093/jnci/89.12.881 Occurrence Handle1:STN:280:ByiA3sbmsFI%3D Occurrence Handle9196255

    Article  CAS  PubMed  Google Scholar 

  12. F Tanaka Y Otake K Yanagihara et al. (2001) ArticleTitleEvaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody Clin Cancer Res 7 3410–3415 Occurrence Handle1:CAS:528:DC%2BD3MXptFaisr0%3D Occurrence Handle11705856

    CAS  PubMed  Google Scholar 

  13. AP Meert M Paesmans B Martin et al. (2002) ArticleTitleThe role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 87 694–701 Occurrence Handle10.1038/sj.bjc.6600551 Occurrence Handle12232748

    Article  PubMed  Google Scholar 

  14. F Tanaka Y Otake K Yanagihara et al. (2003) ArticleTitleGlomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer Cancer Res 63 6791–6794 Occurrence Handle1:CAS:528:DC%2BD3sXosVGnsr0%3D Occurrence Handle14583475

    CAS  PubMed  Google Scholar 

  15. HF Dvorak (2002) ArticleTitleVascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 4368–4380 Occurrence Handle10.1200/JCO.2002.10.088 Occurrence Handle1:CAS:528:DC%2BD38Xpt1CjtL0%3D Occurrence Handle12409337

    Article  CAS  PubMed  Google Scholar 

  16. A Yuan CJ Yu SH Kuo et al. (2001) ArticleTitleVascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer J Clin Oncol 19 432–441 Occurrence Handle1:CAS:528:DC%2BD3MXhtVekt7Y%3D Occurrence Handle11208836

    CAS  PubMed  Google Scholar 

  17. DO Bates TG Cui JM Doughty et al. (2002) ArticleTitleVEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res 62 4123–4131 Occurrence Handle1:CAS:528:DC%2BD38XlsV2ltrw%3D Occurrence Handle12124351

    CAS  PubMed  Google Scholar 

  18. CL Huang D Liu J Nakano et al. (2005) ArticleTitleWnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor – an expression in non-small-cell lung cancer J Clin Oncol 23 8765–8773 Occurrence Handle16314637

    PubMed  Google Scholar 

  19. S Yano Y Nishioka K Izumi et al. (1997) ArticleTitleNovel metastasis model of human lung cancer in SCID mice depleted of NK cells Int J Cancer 67 211–217

    Google Scholar 

  20. S Yano H Nokihara M Hanibuchi et al. (1997) ArticleTitleModel of malignant pleural effusion of human lung adenocarcinoma in SCID mice Oncol Res 9 573–579 Occurrence Handle1:CAS:528:DyaK1cXisVCntr8%3D Occurrence Handle9563004

    CAS  PubMed  Google Scholar 

  21. T Miki S Yano M Hanibuchi et al. (2000) ArticleTitleBone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice Oncol Res 12 209–217 Occurrence Handle1:CAS:528:DC%2BD38XltlOktA%3D%3D Occurrence Handle11417746

    CAS  PubMed  Google Scholar 

  22. H Yanagawa E Takeuchi Y Suzuki et al. (1999) ArticleTitleVascular endothelial growth factor in malignant pleural effusion associated with lung cancer Cancer Immunol Immunother 48 396–400 Occurrence Handle10.1007/s002620050592 Occurrence Handle1:CAS:528:DyaK1MXnsVShs7g%3D Occurrence Handle10501853

    Article  CAS  PubMed  Google Scholar 

  23. S Yano H Shinohara RS Herbst et al. (2000) ArticleTitleProduction of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells Am J Pathol 157 1893–1903 Occurrence Handle1:CAS:528:DC%2BD3MXhsVKrtQ%3D%3D Occurrence Handle11106562

    CAS  PubMed  Google Scholar 

  24. JD Heiss E Papavassilous MJ Merrill et al. (1996) ArticleTitleMechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor J Clin Invest 98 1400–1408 Occurrence Handle1:CAS:528:DyaK28Xlsl2mtb0%3D Occurrence Handle8823305

    CAS  PubMed  Google Scholar 

  25. KH Plate (2001) ArticleTitleFrom angiogenesis to lymphangiogenesis Nat Med 7 151–152 Occurrence Handle10.1038/84579 Occurrence Handle1:CAS:528:DC%2BD3MXhtVyht74%3D Occurrence Handle11175837

    Article  CAS  PubMed  Google Scholar 

  26. T Kajita Y Ohta K Kimura et al. (2001) ArticleTitleThe expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer Br J Cancer 85 255–260 Occurrence Handle10.1054/bjoc.2001.1882 Occurrence Handle1:CAS:528:DC%2BD3MXmtVKht7g%3D Occurrence Handle11461086

    Article  CAS  PubMed  Google Scholar 

  27. M Arinaga T Noguchi S Takeno et al. (2003) ArticleTitleClinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma Cancer (Phila) 97 457–464 Occurrence Handle1:CAS:528:DC%2BD3sXhtFGltL0%3D

    CAS  Google Scholar 

  28. J Holash PC Maisonpierre D Compton et al. (1999) ArticleTitleVessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1994–1998 Occurrence Handle10.1126/science.284.5422.1994 Occurrence Handle1:CAS:528:DyaK1MXktVWntrY%3D Occurrence Handle10373119

    Article  CAS  PubMed  Google Scholar 

  29. F Tanaka S Ishikawa K Yanagihara et al. (2002) ArticleTitleExpression of angiopoietins and its clinical significance in non-small cell lung cancer Cancer Res 62 7124–7129 Occurrence Handle1:CAS:528:DC%2BD38XpsVaht78%3D Occurrence Handle12460935

    CAS  PubMed  Google Scholar 

  30. K Watanabe Y Hasegawa H Yamashita et al. (2004) ArticleTitleVasohibin as an endothelium-derived negative feedback regulator of angiogenesis J Clin Invest 114 898–907 Occurrence Handle10.1172/JCI200421152 Occurrence Handle1:CAS:528:DC%2BD2cXot12gtr8%3D Occurrence Handle15467828

    Article  CAS  PubMed  Google Scholar 

  31. LN Klapper MH Kirschbaum M Sela et al. (2000) ArticleTitleBiochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors Adv Cancer Res 77 25–79 Occurrence Handle1:CAS:528:DC%2BD3cXltl2ktw%3D%3D Occurrence Handle10549355

    CAS  PubMed  Google Scholar 

  32. SJ Kim H Uehara T Karashima et al. (2003) ArticleTitleBlockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice Clin Cancer Res 9 1200–1210 Occurrence Handle1:CAS:528:DC%2BD3sXhvFKiur8%3D Occurrence Handle12631626

    CAS  PubMed  Google Scholar 

  33. A Hirata S Ogawa T Kometani et al. (2002) ArticleTitleZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 2554–2560 Occurrence Handle1:CAS:528:DC%2BD38XjtlGrsbc%3D Occurrence Handle11980649

    CAS  PubMed  Google Scholar 

  34. TJ Lynch DW Bell R Sordella et al. (2004) ArticleTitleActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129–2139 Occurrence Handle10.1056/NEJMoa040938 Occurrence Handle1:CAS:528:DC%2BD2cXktF2js7c%3D Occurrence Handle15118073

    Article  CAS  PubMed  Google Scholar 

  35. AP Meert B Martin P Delmotte et al. (2002) ArticleTitleThe role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis Eur Respir J 20 975–981 Occurrence Handle10.1183/09031936.02.00296502 Occurrence Handle1:STN:280:DC%2BD38nltFCgtg%3D%3D Occurrence Handle12412692

    Article  CAS  PubMed  Google Scholar 

  36. T Kosaka Y Yatabe H Endoh et al. (2004) ArticleTitleMutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 8919–8923 Occurrence Handle10.1158/0008-5472.CAN-04-2818 Occurrence Handle1:CAS:528:DC%2BD2cXhtVOmsL3P Occurrence Handle15604253

    Article  CAS  PubMed  Google Scholar 

  37. T Kanematsu S Yano H Uehara et al. (2003) ArticleTitlePhosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients Oncol Res 13 289–298 Occurrence Handle12688680

    PubMed  Google Scholar 

  38. RK Jain (2002) ArticleTitleTumor angiogenesis and accessibility: role of vascular endothelial growth factor Semin Oncol (Suppl) 16 3–9

    Google Scholar 

  39. O Belvedere F Grossi (2006) ArticleTitleLung cancer highlights from ASCO 2005 Oncologist 11 39–50 Occurrence Handle10.1634/theoncologist.11-1-39 Occurrence Handle16401712

    Article  PubMed  Google Scholar 

  40. DH Johnson L Fehrenbacher WF Novotny et al. (2004) ArticleTitleRandomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184–2191 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWltrg%3D Occurrence Handle15169807

    CAS  PubMed  Google Scholar 

  41. H Goto S Yano H Zhang et al. (2002) ArticleTitleActivity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice Cancer Res 62 3711–3715 Occurrence Handle1:CAS:528:DC%2BD38XltF2jtbw%3D Occurrence Handle12097279

    CAS  PubMed  Google Scholar 

  42. H Goto S Yano Y Matsumori et al. (2004) ArticleTitleSensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin Clin Cancer Res 10 7671–7676 Occurrence Handle10.1158/1078-0432.CCR-04-1171 Occurrence Handle1:CAS:528:DC%2BD2cXhtVanur3M Occurrence Handle15570000

    Article  CAS  PubMed  Google Scholar 

  43. J Randal (2000) ArticleTitleAntiangiogenesis drugs target specific cancers, mechanisms J Natl Cancer Inst 92 520–522 Occurrence Handle1:STN:280:DC%2BD3c3hsFSiuw%3D%3D Occurrence Handle10749899

    CAS  PubMed  Google Scholar 

  44. RS Herbst M Fukuoka J Baselga (2004) ArticleTitleGefitinib: a novel targeted approach to treating cancer Nat Rev Cancer 4 956–965 Occurrence Handle10.1038/nrc1506 Occurrence Handle1:CAS:528:DC%2BD2cXhtVarsLjJ Occurrence Handle15573117

    Article  CAS  PubMed  Google Scholar 

  45. JG Paez PA Janne JC Lee et al. (2004) ArticleTitleEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497–1500 Occurrence Handle10.1126/science.1099314 Occurrence Handle1:CAS:528:DC%2BD2cXksVGmsbs%3D Occurrence Handle15118125

    Article  CAS  PubMed  Google Scholar 

  46. F Cappuzzo FR Hirch E Rossi et al. (2005) ArticleTitleEpidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643–655 Occurrence Handle1:CAS:528:DC%2BD2MXjvFymt70%3D Occurrence Handle15870435

    CAS  PubMed  Google Scholar 

  47. F Cappuzzo E Magrini GL Ceresoli et al. (2004) ArticleTitleAkt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 1133–1141 Occurrence Handle1:CAS:528:DC%2BD2cXntFamsbg%3D Occurrence Handle15292385

    CAS  PubMed  Google Scholar 

  48. S Kakiuchi Y Daigo N Ishikawa et al. (2004) ArticleTitlePrediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839) Hum Mol Genet 13 3029–3043 Occurrence Handle10.1093/hmg/ddh331 Occurrence Handle1:CAS:528:DC%2BD2cXhtVClu7rE Occurrence Handle15496427

    Article  CAS  PubMed  Google Scholar 

  49. J Baselga (2002) ArticleTitleWhy the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 IssueIDsuppl 4 2–8 Occurrence Handle1:CAS:528:DC%2BD38XnsFOiurw%3D Occurrence Handle12202782

    CAS  PubMed  Google Scholar 

  50. S Yano RS Herbst S Shinohara et al. (2000) ArticleTitleTreatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation Clin Cancer Res 6 957–965 Occurrence Handle1:CAS:528:DC%2BD3cXisVaqurw%3D Occurrence Handle10741721

    CAS  PubMed  Google Scholar 

  51. D Strumberg H Richly RA Hilger et al. (2005) ArticleTitlePhase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 965–972 Occurrence Handle1:CAS:528:DC%2BD2MXit1Ggu7c%3D Occurrence Handle15613696

    CAS  PubMed  Google Scholar 

  52. SR Wedge DJ Ogilvie M Dukes et al. (2002) ArticleTitleZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645–4655 Occurrence Handle1:CAS:528:DC%2BD38XmsVShsL8%3D Occurrence Handle12183421

    CAS  PubMed  Google Scholar 

  53. F Ciardiello R Caputo V Damiano et al. (2003) ArticleTitleAntitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 1546–1556 Occurrence Handle1:CAS:528:DC%2BD3sXislerur8%3D Occurrence Handle12684431

    CAS  PubMed  Google Scholar 

  54. Matsumori Y, Yano S, Goto H, et al. (2006) ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res (in press)

  55. S Yano H Muguruma Y Matsumori et al. (2005) ArticleTitleAntitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice Clin Cancer Res 11 IssueID24 pt 1 8789–8798 Occurrence Handle1:CAS:528:DC%2BD2MXhtlWrsbjE Occurrence Handle16361567

    CAS  PubMed  Google Scholar 

  56. H Minami H Ebi M Tahara et al. (2002) ArticleTitleA phase I study of an oral VEGF receptor tyrosine kinase inhibitor, ZD6474, in Japanese patients with solid tumors Proc Am Soc Clin Oncol 22 194

    Google Scholar 

  57. H Hurwitz SN Holden SG Eckhaedt et al. (2002) ArticleTitleClinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors Proc Am Soc Clin Oncol 21 82a

    Google Scholar 

  58. RS Herbst DH Johson E Mininberg et al. (2005) ArticleTitlePhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2544–2555 Occurrence Handle1:CAS:528:DC%2BD2MXjvVyktLY%3D Occurrence Handle15753462

    CAS  PubMed  Google Scholar 

  59. RS Kerbel (2001) ArticleTitleClinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results J Clin Oncol 19 IssueIDsuppl 18 45S–51S Occurrence Handle1:CAS:528:DC%2BD3MXnsVKqtrs%3D Occurrence Handle11560971

    CAS  PubMed  Google Scholar 

  60. RS Herbst NA Mullani DW Davis et al. (2002) ArticleTitleDevelopment of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin J Clin Oncol 20 3804–3814 Occurrence Handle1:CAS:528:DC%2BD38XntVyns7o%3D Occurrence Handle12228200

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan

    Seiji Yano, Yuka Matsumori, Kenji Ikuta, Hirokazu Ogino, Tamir Doljinsuren & Saburo Sone

Authors
  1. Seiji Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuka Matsumori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Ikuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirokazu Ogino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tamir Doljinsuren
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Saburo Sone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saburo Sone.

About this article

Cite this article

Yano, S., Matsumori, Y., Ikuta, K. et al. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 11, 73–81 (2006). https://doi.org/10.1007/s10147-006-0568-3

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-006-0568-3

Key words

Search

Navigation